Genetic Analytics - ProtaGene

Cell & Gene Analytics

Genome and Gene Editing Analysis

hero-animation

Genome and Gene Editing Analytics

Genome editing using designer nucleases such as CRISPR/Cas9, ZFNs, and TALENs allow the targeted introduction of genetic material into a specific locus. However, undesired genome modifications potentially disrupting the functionality of otherwise normal genes may arise, thus raising safety concerns.

Icon for On- and Off-Target Analysis

On- and Off-Target Analysis

ProtaGene offers a versatile and cost-effective assay for gene editing safety assessment. We adapted our Shearing Extension Primer Tag Selection Ligation-Mediated PCR (S-EPTS/LM PCR) method for the genome-wide detection and quantification of on- and off-target alterations. In combination with robust in-house bioinformatics pipelines, our assay reliably quantify the ratios between the desired targeted integration and non-desired outcomes such as translocations and indels.

  • bullet Created with Sketch.
    PCR-Based
  • bullet Created with Sketch.
    NGS-Based
Icon for Immune Repertoire Analysis

Immune Repertoire Analysis

Adaptive immune response generates T cell and B cell receptors (TCRs and BCRs) that comprise an organism’s immune repertoire. Immune repertoire analysis has many applications, including cancer diagnosis, immunotherapy monitoring, gene therapy development, or infectious diseases.

The advent of high-throughput sequencing technologies have allowed for the comprehensive monitoring of the immune repertoire size, diversity and dynamics.

ProtaGene offers both PCR- and target enrichment sequencing-based approaches for the high-throughput analysis of T cell and B cell receptors from a wide range of sample input material.

  • bullet Created with Sketch.
    TES-Based
  • bullet Created with Sketch.
    RACE-PCR

Analytical Solutions from Research to Market

Group Created with Sketch.
Research
Preclinical
Group 2 Created with Sketch.

Discovery – Pre-clinical

Biologic Candidate Evaluation, Optimization and Selection into IND

Group 3 Created with Sketch.
Phase I
Phase II
Phase III
Group 4 Created with Sketch.

Phase I – Phase III

Release, Clinical Data and Characterization Packages for Accelerating Phase I-III Programs through BLA

Group Created with Sketch.
Registration
Market
Group 2 Created with Sketch.

Registration – Market

Commercial-Stage Comparability Testing by Qualified Advanced Methods

Cell and Gene Therapeutic Platform Expertise

Our deep experience assembling a broad range of cell and gene therapy platforms from research through commercialization helps the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key cell and gene therapy platform development areas include:

  • bullet Created with Sketch.

    Capsid-based Vectors

    • AAVs (Multiple Serotypes and Engineered Vectors)
    • Novel Systems
    • Adenovirus
  • bullet Created with Sketch.

    Complex, Envelope Vectors

    • Lentivirus
    • Gammaretrovirus 
    • Novel Viruses
  • bullet Created with Sketch.

    Non-viral Vectors

    • Polynucleotide (RNA/DNA) Formulations
    • Lipid Nanoparticles
    • Transposons
    • Plasmids
  • bullet Created with Sketch.

    Genetic Engineering

    • TALEN
    • CRISPR/Cas9
    • Zinc-finger Nucleases
Our Analytical Systems_Left Created with Sketch.

Analytical Systems

Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.

Our Analytical Systems_right Created with Sketch.

Subscribe to Our Email List

Consent

Talk to Our Experts

Discover how ProtaGene can support your development programs

Contact Us